Clinical impact of influenza vaccination after ST- and
non-ST-segment elevation myocardial infarction- from the IAMI
trial

J 2023

Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction- from the IAMI trial

FROEBERT, Ole, Matthias GOETBERG, David ERLINGE, Zubair AKHTAR, Evald H CHRISTIANSEN et. al.

Basic information

Original name

Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction- from the IAMI trial

Authors

FROEBERT, Ole, Matthias GOETBERG, David ERLINGE, Zubair AKHTAR, Evald H CHRISTIANSEN, Chandini R MACINTYRE, Keith G OLDROYD, Zuzana MOTOVSKA, Andrejs ERGLIS, Rasmus MOER, Ota HLINOMAZ (203 Czech Republic, belonging to the institution), Lars JAKOBSEN, Thomas ENGSTROM, Lisette O JENSEN, Christian O FALLESEN, Svend E JENSEN, Oskar ANGERAS, Fredrik CALAIS, Amra KAREGREN, Joerg LAUERMANN, Arash MOKHTARI, Johan NILSSON, Jonas PERSSON, Per STALBY, Abu K M M ISLAM, Afzalur RAHMAN, Fazila MALIK, Sohel CHOUDHURY, Timothy COLLIER, Stuart J POCOCK and John PERNOW

Edition

American Heart Journal, New York, MOSBY-ELSEVIER, 2023, 0002-8703

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.800 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.ahj.2022.10.005

UT WoS

000888092200001

Keywords in English

influenza vaccination; myocardial infarction

Abstract

V originále

Background Influenza vaccination early after myocardial infarction (MI) improves prognosis but vaccine effectiveness may differ dependent on type of MI. Methods A total of 2,571 participants were prospectively enrolled in the Influenza vaccination after myocardial infarction (IAMI) trial and randomly assigned to receive in-hospital inactivated influenza vaccine or saline placebo. The trial was conducted at 30 centers in eight countries from October 1, 2016 to March 1, 2020. Here we report vaccine effective-ness in the 2,467 participants with ST-segment elevation MI (STEMI, n = 1,348) or non-ST-segment elevation MI (NSTEMI, n = 1,119). The primary endpoint was the composite of all-cause death, MI, or stent thrombosis at 12 months. Cumulative incidence of the primary and key secondary endpoints by randomized treatment and NSTEMI/STEMI was estimated using the Kaplan-Meier method. Treatment effects were evaluated with formal interaction testing to assess for effect modification. Results Baseline risk was higher in participants with NSTEMI. In the NSTEMI group the primary endpoint occurred in 6.5% of participants assigned to influenza vaccine and 10.5% assigned to placebo (hazard ratio [HR], 0.60; 95% CI, 0.39-0.91), compared to 4.1% assigned to influenza vaccine and 4.5% assigned to placebo in the STEMI group (HR, 0.90; 95% CI, 0.54-1.50, P = .237 for interaction). Similar findings were seen for the key secondary endpoints of all-cause death and cardiovascular death. The Kaplan-Meier risk difference in all-cause death at one year was more pronounced in participants with NSTEMI (NSTEMI: HR, 0.47; 95% CI 0.28-0.80, STEMI: HR, 0.86; 95% CI, 0.43-1.70, interaction P = .028). Conclusions The beneficial effect of influenza vaccination on adverse cardiovascular events may be enhanced in patients with NSTEMI compared to those with STEMI.

Citovat

FROEBERT, Ole, Matthias GOETBERG, David ERLINGE, Zubair AKHTAR, Evald H CHRISTIANSEN, Chandini R MACINTYRE, Keith G OLDROYD, Zuzana MOTOVSKA, Andrejs ERGLIS, Rasmus MOER, Ota HLINOMAZ, Lars JAKOBSEN, Thomas ENGSTROM, Lisette O JENSEN, Christian O FALLESEN, Svend E JENSEN, Oskar ANGERAS, Fredrik CALAIS, Amra KAREGREN, Joerg LAUERMANN, Arash MOKHTARI, Johan NILSSON, Jonas PERSSON, Per STALBY, Abu K M M ISLAM, Afzalur RAHMAN, Fazila MALIK, Sohel CHOUDHURY, Timothy COLLIER, Stuart J POCOCK and John PERNOW. Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction- from the IAMI trial. American Heart Journal. New York: MOSBY-ELSEVIER, 2023, vol. 255, January 2023, p. 82-89. ISSN 0002-8703. Available from: https://dx.doi.org/10.1016/j.ahj.2022.10.005.

@article{2417952,
   author = {Froebert, Ole and Goetberg, Matthias and Erlinge, David and Akhtar, Zubair and Christiansen, Evald H and MacIntyre, Chandini R and Oldroyd, Keith G and Motovska, Zuzana and Erglis, Andrejs and Moer, Rasmus and Hlinomaz, Ota and Jakobsen, Lars and Engstrom, Thomas and Jensen, Lisette O and Fallesen, Christian O and Jensen, Svend E and Angeras, Oskar and Calais, Fredrik and Karegren, Amra and Lauermann, Joerg and Mokhtari, Arash and Nilsson, Johan and Persson, Jonas and Stalby, Per and Islam, Abu K M M and Rahman, Afzalur and Malik, Fazila and Choudhury, Sohel and Collier, Timothy and Pocock, Stuart J and Pernow, John},
   article_location = {New York},
   article_number = {January 2023},
   doi = {http://dx.doi.org/10.1016/j.ahj.2022.10.005},
   keywords = {influenza vaccination; myocardial infarction},
   language = {eng},
   issn = {0002-8703},
   journal = {American Heart Journal},
   title = {Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction- from the IAMI trial},
   url = {https://www.sciencedirect.com/science/article/pii/S0002870322001983?via%3Dihub},
   volume = {255},
   year = {2023}
}

TY  - JOUR
ID  - 2417952
AU  - Froebert, Ole - Goetberg, Matthias - Erlinge, David - Akhtar, Zubair - Christiansen, Evald H - MacIntyre, Chandini R - Oldroyd, Keith G - Motovska, Zuzana - Erglis, Andrejs - Moer, Rasmus - Hlinomaz, Ota - Jakobsen, Lars - Engstrom, Thomas - Jensen, Lisette O - Fallesen, Christian O - Jensen, Svend E - Angeras, Oskar - Calais, Fredrik - Karegren, Amra - Lauermann, Joerg - Mokhtari, Arash - Nilsson, Johan - Persson, Jonas - Stalby, Per - Islam, Abu K M M - Rahman, Afzalur - Malik, Fazila - Choudhury, Sohel - Collier, Timothy - Pocock, Stuart J - Pernow, John
PY  - 2023
TI  - Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction- from the IAMI trial
JF  - American Heart Journal
VL  - 255
IS  - January 2023
SP  - 82-89
EP  - 82-89
PB  - MOSBY-ELSEVIER
SN  - 00028703
KW  - influenza vaccination
KW  - myocardial infarction
UR  - https://www.sciencedirect.com/science/article/pii/S0002870322001983?via%3Dihub
N2  - Background Influenza vaccination early after myocardial infarction (MI) improves prognosis but vaccine effectiveness may differ dependent on type of MI. Methods A total of 2,571 participants were prospectively enrolled in the Influenza vaccination after myocardial infarction (IAMI) trial and randomly assigned to receive in-hospital inactivated influenza vaccine or saline placebo. The trial was conducted at 30 centers in eight countries from October 1, 2016 to March 1, 2020. Here we report vaccine effective-ness in the 2,467 participants with ST-segment elevation MI (STEMI, n = 1,348) or non-ST-segment elevation MI (NSTEMI, n = 1,119). The primary endpoint was the composite of all-cause death, MI, or stent thrombosis at 12 months. Cumulative incidence of the primary and key secondary endpoints by randomized treatment and NSTEMI/STEMI was estimated using the Kaplan-Meier method. Treatment effects were evaluated with formal interaction testing to assess for effect modification. Results Baseline risk was higher in participants with NSTEMI. In the NSTEMI group the primary endpoint occurred in 6.5% of participants assigned to influenza vaccine and 10.5% assigned to placebo (hazard ratio [HR], 0.60; 95% CI, 0.39-0.91), compared to 4.1% assigned to influenza vaccine and 4.5% assigned to placebo in the STEMI group (HR, 0.90; 95% CI, 0.54-1.50, P = .237 for interaction). Similar findings were seen for the key secondary endpoints of all-cause death and cardiovascular death. The Kaplan-Meier risk difference in all-cause death at one year was more pronounced in participants with NSTEMI (NSTEMI: HR, 0.47; 95% CI 0.28-0.80, STEMI: HR, 0.86; 95% CI, 0.43-1.70, interaction P = .028). Conclusions The beneficial effect of influenza vaccination on adverse cardiovascular events may be enhanced in patients with NSTEMI compared to those with STEMI.
ER  -

FROEBERT, Ole, Matthias GOETBERG, David ERLINGE, Zubair AKHTAR, Evald H CHRISTIANSEN, Chandini R MACINTYRE, Keith G OLDROYD, Zuzana MOTOVSKA, Andrejs ERGLIS, Rasmus MOER, Ota HLINOMAZ, Lars JAKOBSEN, Thomas ENGSTROM, Lisette O JENSEN, Christian O FALLESEN, Svend E JENSEN, Oskar ANGERAS, Fredrik CALAIS, Amra KAREGREN, Joerg LAUERMANN, Arash MOKHTARI, Johan NILSSON, Jonas PERSSON, Per STALBY, Abu K M M ISLAM, Afzalur RAHMAN, Fazila MALIK, Sohel CHOUDHURY, Timothy COLLIER, Stuart J POCOCK and John PERNOW. Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction- from the IAMI trial. \textit{American Heart Journal}. New York: MOSBY-ELSEVIER, 2023, vol.~255, January 2023, p.~82-89. ISSN~0002-8703. Available from: https://dx.doi.org/10.1016/j.ahj.2022.10.005.

Detailed Information on Publication Record